Q2 2026 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Aug 5, 2026 / 12:30 PM GMT

Release Date Price: $9.07 (+0.55%)

Transcript 10-Q8-K

Key Points

Positve

Completed enrollment of the largest blinded hereditary angioedema (HAE) trial ever for Navenabar ahead of schedule, with top-line data expected in Q3 2027.
Orladeo oral pellets for pediatric HAE patients started shipping, with 47 prescriptions received by July 31, exceeding full-year 2026 expectations.
Total revenue increased 45% year-over-year on a comparable basis, driven by strong Orladeo growth and the Navenabar European license upfront payment.
Non-GAAP operating profit reached $113.2 million in Q2, reflecting strong profitability and disciplined cost management.
Improved payer approval rate for Orladeo to 84%, up from 83% a year ago, despite a competitive landscape.
Strategic shift to external innovation and closure of internal discovery programs is expected to reduce operating costs, with guidance lowered to $420-$440 million.
Strong balance sheet with over $350 million in cash, generating positive cash flow even excluding the license upfront payment.

Negative

Manufacturing delay for Orladeo oral pellets impacted the pediatric launch timeline, though early demand is strong.
Competition from new injectable HAE therapies is causing some patient switches away from Orladeo, particularly to newer products.
The company discontinued internal discovery programs and closed its Birmingham facility, which may limit internal pipeline innovation.
Navenabar's pivotal study will remain blinded for 12 months, delaying top-line data until Q3 2027, which is later than initially expected.
Orladeo's paid rate is expected to decline by 1-2% in the second half of the year due to new patient mix, potentially impacting revenue growth.
The transition to a new sole-source pharmacy (CareMed) may cause temporary disruptions in Orladeo shipments, though long-term benefits are anticipated.
The company's BD strategy focuses on external assets, which carries execution risks and may not yield immediate pipeline additions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BCRX.OQ - BioCryst Pharmaceuticals, Inc.
Q2 2026 BioCryst Pharmaceuticals Inc Earnings Call
Aug 05, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to the BioCrys second quarter 2026 earnings call.

At this time, all participants are in a listen-only mode.

After the speaker presentation, there will be a question-and-answer session, to ask a question during the session, you will need to press 11 on your telephone.

You will then hear an automated message advising your hand has been raised to withdraw your question, please press star 11 again.

Please be advised that today's conference is being recorded.

It is now my pleasure to introduce Nick Wilder.

Good morning and welcome to BioCrys second quarter 2026 corporate update and financial results conference call.

Participating with

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.